TP53 and non-small cell lung carcinoma: In 2023, the largest molecular study identified wild-type RB1/TP53 tumors, SCLCs with STK11 mutation (also mutation in the PIK3CA and PTEN pathway were found), and SCLCs derived from transformation of NSCLC with different molecular characteristics [72].